share_log

NewAmsterdam Pharma Debuts As Publicly Traded Co. Focused On Developing Obicetrapib As A Potential Preferred Therapy For High Risk Cardiovascular Disease Patients

NewAmsterdam Pharma Debuts As Publicly Traded Co. Focused On Developing Obicetrapib As A Potential Preferred Therapy For High Risk Cardiovascular Disease Patients

NewAmsterdam Pharma 作为上市公司首次亮相专注于开发Obicetrapib作为高危心血管疾病患者的潜在首选疗法
Benzinga Real-time News ·  2022/11/23 08:04

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 --

-- 与由Frazier Healthcare Partners子公司赞助的特殊目的收购公司Frazier Lifesciences收购公司的业务合并交易于11月完成 2022 年 22 日-

-- Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity ("PIPE"), led by Frazier Healthcare Partners and Bain Capital Life Sciences --

— 由Frazier Healthcare Partners和Bain Capital Life Sciences牵头的同时关闭、超额认购和扩大了约2.35亿美元的公募股权（“PIPE”）私人投资——

-- Gross proceeds from the transactions totaled approximately $328 million, combining approximately $93 million from the former FLAC trust account (reflecting a final redemption rate of approximately 32 percent) and the concurrent PIPE financing; expected to extend cash runway through 2026, beyond all expected Phase 3 readouts for cardiovascular disease, including PREVAIL CVOT study --

--交易总收益约为3.28亿美元， 将来自前FLAC信托账户（最终赎回率约为32％）和同时进行的PIPE融资的约9300万美元；预计将把现金流延长至2026年，超过所有预期的心血管疾病第三阶段读数，包括PREVAL CVOT研究——

-- Listed company to be named NewAmsterdam Pharma Company N.V. --

— 上市公司将被命名为 NewAmsterdam Pharma Company N.V. —

-- Ordinary shares and warrants to commence trading on the Nasdaq Capital Market under the ticker symbols "NAMS" and "NAMSW," respectively on November 23 –

— 普通股和认股权证将于11月23日在纳斯达克资本市场开始交易，股票代码分别为 “NAMS” 和 “NAMSW” —

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发